Liebl Andreas, Henrichs Helmut R, Heinemann Lutz, Freckmann Guido, Biermann Eberhard, Thomas Andreas
m&i-Fachklinik Bad Heilbrunn, Diabetes Center, Department of Internal Medicine, Wörnerweg 30, 83670 Bad Heilbrunn, Germany.
J Diabetes Sci Technol. 2013 Mar 1;7(2):500-19. doi: 10.1177/193229681300700227.
Continuous glucose monitoring (CGM) is an essential tool for modern diabetes therapy. Randomized controlled studies have provided evidence that hemoglobin A1c (HbA1c) results can be improved in patients with type 1 diabetes with elevated baseline HbA1c when using CGM frequently enough and that the frequency and duration of hypoglycemic events can be reduced in patients with satisfactory baseline HbA1c. The CGM group within the Working Group Diabetes Technology (AGDT) of the German Diabetes Association (DDG) has defined evidence-based indications for the practical use of CGM in this consensus statement related to hypoglycemia (frequent, severe, or nocturnal) or hypoglycemia unawareness, insufficient metabolic control despite use of all possible therapeutic options and patient compliance, pregnancy associated with inadequate blood glucose results, and the need for more than 10 blood glucose measurements per day. Contraindications and defined preconditions for the successful use of CGM should be considered.
连续血糖监测（CGM）是现代糖尿病治疗的重要工具。随机对照研究已提供证据表明，对于基线糖化血红蛋白（HbA1c）升高的1型糖尿病患者，足够频繁地使用CGM可改善HbA1c结果；对于基线HbA1c达标的患者，可减少低血糖事件的发生频率和持续时间。德国糖尿病协会（DDG）糖尿病技术工作组（AGDT）中的CGM小组在本关于低血糖（频繁、严重或夜间低血糖）或低血糖无意识、尽管使用了所有可能的治疗方案和患者依从性但代谢控制仍不足、血糖结果不理想的妊娠情况以及每天需要进行超过10次血糖测量的共识声明中，明确了CGM实际应用的循证指征。应考虑CGM成功使用的禁忌症和既定前提条件。
